Colibri Heart Valve LLC v. Edwards Lifesciences: Federal Circuit Appeal Voluntarily Dismissed in Heart Valve Patent Dispute
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Colibri Heart Valve LLC v. Edwards Lifesciences Co. |
| Numéro de dossier | 24-1272 (Fed. Cir.) |
| Tribunal | Federal Circuit (Appeal from PTAB/District Court) |
| Durée | Dec 2023 – Mar 2024 84 Days |
| Résultat | Voluntary Dismissal — No Merits Ruling |
| Brevet en cause | |
| Produits incriminés | Edwards Lifesciences’ TAVR Product Lines |
Aperçu du dossier
Les parties
⚖️ Demandeur
Patent-holding entity asserting rights in transcatheter heart valve technology — an innovative delivery mechanism that eliminates the need for open-heart surgery.
🛡️ Défendeur
Among the world’s foremost structural heart disease companies, with deep commercial investments in transcatheter aortic valve replacement (TAVR) technology.
Brevet en cause
This case centered on U.S. Patent No. 9,737,400 B2 — covering a percutaneously deliverable heart valve incorporating folded membrane cusps with integral leaflets — a technology area at the heart of a multi-billion-dollar medical device market.
- • US 9,737,400 B2 — Percutaneously deliverable heart valve featuring folded membrane cusps with integral leaflets.
Developing a medtech device?
Check if your heart valve design might infringe this or related patents before launch.
Le verdict et l'analyse juridique
Résultat
The Federal Circuit dismissed Case No. 24-1272 pursuant to Federal Rule of Appellate Procedure 42(b) upon joint stipulation of the parties on March 12, 2024. Each side agreed to bear its own costs. No damages were awarded, no injunctive relief was issued, and no precedential opinion was published. The underlying patent’s validity status following this dismissal is not publicly resolved by this proceeding alone.
Principales questions juridiques
The designated verdict cause — Invalidity/Cancellation Action — indicates that Edwards Lifesciences mounted a challenge to the patentability of U.S. Patent No. 9,737,400 B2. Common grounds in such proceedings include obviousness (35 U.S.C. § 103), anticipation (35 U.S.C. § 102), or enablement/written description (35 U.S.C. § 112). The voluntary dismissal, agreed to by both parties, prevents any determination of which arguments were prevailing or failing at the appellate stage. Critically, an FRCP 42(b) dismissal at the Federal Circuit level does not constitute a ruling on the merits — leaving the underlying record’s outcome as the operative legal result for the patent’s validity posture.
Analyse de la liberté d'exploitation (FTO)
This case highlights critical IP risks in structural heart valve design. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- Voir tous les brevets liés à ce domaine technologique
- See which companies are most active in heart valve patents
- Comprendre les modèles d'interprétation des revendications
🔍 Vérifier les risques liés à mon produit
Effectuez une analyse FTO complète pour votre propre technologie ou produit.
- Saisissez la description de votre produit ou ses caractéristiques techniques.
- L'IA identifie les brevets susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
Risque lié aux brevets actifs
Percutaneous valve designs with folded cusps
Related Filings
Monitor for continuation patents
Sortie stratégique
Negotiated settlement over judicial ruling
✅ Points clés à retenir
A joint Federal Circuit dismissal under FRCP 42(b) produces no precedential ruling and leaves underlying validity questions unresolved.
Rechercher la jurisprudence connexe →The 84-day appellate lifespan signals active settlement negotiations likely began at or before the filing date in high-stakes medtech disputes.
Explorer les précédents →Invalidity/cancellation appeals at the Federal Circuit remain viable leverage points for negotiating licensing outcomes.
Analyser les stratégies contentieuses →U.S. Patent No. 9,737,400 B2 remains a live patent asset requiring monitoring for any continuation filings or related family members.
Surveiller cette famille de brevets →The case illustrates the value of early appellate settlement analysis in high-cost IP disputes, often preferable to prolonged uncertainty.
Analyser les tendances en matière de règlement →Foire aux questions
The case involved U.S. Patent No. 9,737,400 B2 (Application No. 13/326,196), covering a percutaneously deliverable heart valve with folded membrane cusps and integral leaflets.
The parties jointly stipulated to dismissal under Federal Rule of Appellate Procedure 42(b), with each side bearing its own costs. No merits ruling was issued.
No. A voluntary dismissal under FRCP 42(b) does not constitute a ruling on patentability. The validity of U.S. Patent No. 9,737,400 B2 was not adjudicated by this Federal Circuit proceeding.
Companies operating in the medtech space, especially with percutaneous valve designs, can protect themselves by conducting robust freedom-to-operate (FTO) analysis before product launch, thoroughly documenting design evolution, developing design-around strategies for high-risk elements, and strategically filing their own patents. PatSnap Eureka’s FTO tools help R&D and IP teams identify potentially blocking patents before products go to market.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- United States Court of Appeals for the Federal Circuit — Case 24-1272
- U.S. Patent No. 9,737,400 B2 — Google Patents
- Institut d'information juridique de Cornell — Règle fédérale de procédure d'appel 42(b)
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.